Mustang could pick up another Priority Review voucher

1 September 2020

Mustang Bio (Nasdaq: MBIO) has been awarded Rare Pediatric Disease designation for MB-207 from the US Food and Drug Administration.

The firm is focused on cell and gene therapies to treat hematologic cancers, solid tumors and rare genetic diseases.

MB-207 is a lentiviral gene therapy for the treatment of certain people with X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease.

The firm, which already received the designation for people with newly diagnosed XSCID, is also developing MB-207 for people who have been treated with a hematopoietic stem cell transplantation (HSCT), without success.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK